Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Dermatol. 2010 Aug;22(3):349-52. doi: 10.5021/ad.2010.22.3.349. Epub 2010 Aug 5.

Recalcitrant atopic dermatitis treated with omalizumab.

Author information

  • 1Department of Dermatology, Seoul National University College of Medicine, Seongnam, Korea.

Abstract

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcepsilonRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea.

KEYWORDS:

Atopic dermatitis; Biologies; Omalizumab

PMID:
20711278
[PubMed]
PMCID:
PMC2917695
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1
Fig. 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Dermatological Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk